In Vitro Assessment of a Chemically Synthesized Shiga Toxin Receptor Analog Attached to Chromosorb P (Synsorb Pk) as a Specific Absorbing Agent of Shiga Toxin 1 and 2
Open Access
- 1 April 1999
- journal article
- research article
- Published by Wiley in Microbiology and Immunology
- Vol. 43 (4) , 331-337
- https://doi.org/10.1111/j.1348-0421.1999.tb02413.x
Abstract
A synthetic analog of Shiga toxin (Stx) receptor (Synsorb Pk) was quantitatively assessed to determine whether it can protect human renal adenocarcinoma cells (ACHN cells) from the cytotoxicity of Stx1 and Stx2 by coincubation experiments. Coincubation of 100 and 20 ng of Stx1 and Stx2 with 50 mg of Synsorb Pk for 1 hr at 37 C in 1 ml of Eagle's Minimum Essential Medium supplemented with 1% (v/v) nonessential amino acid and 10% (v/v) fetal calf serum protected 50% of the cells from the cytotoxic effect. Chromosorb P, an inert matrix control, did not absorb the Stxs at all. Heat‐treatment (boiled for 10 min) to Synsorb Pk caused a 50% decrease in Stx2‐binding activity, but did not effect the Stx1 binding. Further, Stxs bound to Synsorb Pk could be demonstrated. When 20 mg of Synsorb Pk was coincubated for 30 min at 37 C in 1 ml of phosphate‐buffered saline with 1 and 10 ng or more of Stx1 or Stx2, respectively, the toxins could be detected on the surface when the bound toxins on Synsorb Pk were used as the solid phase in enzyme immunoassay. The amount of 100 ng/ml of both Stx1 and Stx2 appeared to saturate 20 mg/ml of Synsorb Pk after coincubating for 30 min at 37 C. While assessing the Stxs' binding activity to Synsorb Pk, it was demonstrated that Stx1 had a higher affinity to Pk trisaccharide than Stx2. These observations provide useful information on the effectiveness of Synsorb Pk to trap and eliminate free Stxs produced in the gut of patients infected by Stx‐producing Escherichia coli, and to prevent the progression of hemorrhagic colitis to hemolytic uremic syndrome.Keywords
This publication has 27 references indexed in Scilit:
- A Phase I Study of Chemically Synthesized Verotoxin (Shiga-like Toxin) Pk-Trisaccharide Receptors Attached to Chromosorb for Preventing Hemolytic-Uremic SyndromeThe Journal of Infectious Diseases, 1995
- Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndromeThe Journal of Pediatrics, 1994
- Investigation of Shiga-like Toxin Binding to Chemically Synthesized Oligosaccharide SequencesThe Journal of Infectious Diseases, 1991
- Verotoxin Receptor Glycolipid in Human Renal TissueNephron, 1989
- Globotriosyl ceramide is specifically recognized by the escherichia coli verocytotoxin 2Biochemical and Biophysical Research Communications, 1988
- Cloning of a Vero toxin (VT2) gene from a VT2-converting phage isolated fromEscherichia coli0157: H7FEMS Microbiology Letters, 1987
- Cloning of a Vero toxin (VT1, Shiga-like toxin I) gene from a VT1-converting phage isolated fromEscherichia coliO157:H7FEMS Microbiology Letters, 1987
- The Association Between Idiopathic Hemolytic Uremic Syndrome and Infection by Verotoxin-Producing Escherichia coliThe Journal of Infectious Diseases, 1985
- Hemorrhagic Colitis Associated with a RareEscherichia coliSerotypeNew England Journal of Medicine, 1983
- CYTOTOXIC ESCHERICHIA COLI 0157:H7 ASSOCIATED WITH HAEMORRHAGIC COLITIS IN CANADAThe Lancet, 1983